Genfleet Therapeutics-B (02595): GFH375 (an oral KRAS G12D inhibitor) has entered a Phase II study for first-line treatment of non-small cell lung cancer, exploring multiple therapeutic regimens including monotherapy, combination with EGFR monoclonal anti